Tuesday, February 27, 2018
ARMS Medical, a supplier of advanced surgical technologies and tools, and Tissue Regenix BioSurgery, an international medical technology company, today announced they have entered into an exclusive distributor agreement for DermaPure® dermal allograft. The multi-year agreement gives ARMS Medical exclusive rights to distribute the Tissue Regenix biologic to hospitals and surgeons throughout the United States for use in urology and gynecology procedures.
David Pennington, vice president of sales for Tissue Regenix BioSurgery, stated, “We chose ARMS Medical as our exclusive distributor because of their strong relationships with Key Opinion Leaders in the urogyn space. Additionally, they are known for bringing innovation to women’s pelvic health solutions. ARMS Medical has helped us extend the use of DermaPure into pelvic floor surgery which could open the opportunity for a more novel approach compared to existing technologies. Together, we are providing education and onboarding for surgeons with the goal of improving patient outcomes and satisfaction.”
Rob Greer, Founder of ARMS Medical, commented “Our strong partnership with Tissue Regenix is advancing the treatment options for pelvic floor surgery. We believe DermaPure allograft is the optimal solution for repairing pelvic organ prolapse and other conditions, and it is a key component of our suite of innovative products. This distribution agreement will empower ARMS Medical to expand adoption of DermaPure by hospitals and surgeons for the benefit of women.”
